Who
Peter Ashley Marks
Director
Company insider
Files Form 4 as: Director, Alterity Therapeutics.
In numbers
- Trades disclosed
- 4
- Buys
- 1
- Sells
- 0
- Bought
- $48K
- Sold
- $0
- Companies
- 1
- Companies where not an officer
- 1
- First trade
- 31 Aug 2026
- Last trade
- 31 Aug 2026
- Last filed
- 8 Sep 2026
Companies traded
Activity over time
1 Aug – 1 Oct
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 31 Aug 2026filed 8 Sep 2026 | ATHE Alterity TherapeuticsBiotechnology | SEC FORM 4 Bought | $24K47,620 at $0.50 | filing |
| 31 Aug 2026filed 8 Sep 2026 | ATHE Alterity Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code P | $24K47,620 at $0.50 | filing |
| 31 Aug 2026filed 8 Sep 2026 | ATHE Alterity Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code P | $24K47,620 at $0.50 | filing |
| 31 Aug 2026filed 8 Sep 2026 | ATHE Alterity TherapeuticsBiotechnology | SEC FORM 4 Bought | $24K47,620 at $0.50 | filing |
News
Peter Ashley Marks Buys 47,620 Shares of Alterity Therapeutics (NASDAQ:ATHE) Stockthemarketsdaily.com · 9 Sep 2026Alterity Therapeutics (NASDAQ:ATHE) Shares Climb 0.8% – Still a Buy?ATHE · dailypolitical.com · 22 Oct 2026
1 headline in the last 90 days name Peter Ashley Marks; 1 article from the last 14 days about the 1 company they traded most, at most three about any one of them.